Abstract
The newly developed COVID-19 vaccines have established a safe profile, yet some individuals experience a wide range of adverse events. Recently, thyroid dysfunction, including Graves’ disease, has been observed after administration of different COVID-19 vaccines, although causality remains a matter of debate. The aim of this systematic review was to examine the available literature and provide an overview of reported cases of Graves’ disease following COVID-19 vaccination. We identified 21 eligible articles which included 57 patients with Graves’ disease following COVID-19 vaccination. Fourteen participants were males (25%, 14/57) and 43 (75%, 44/57) were females with a mean age of 44.3 years. The most common presenting symptom was palpitations (63%, 27/43) followed by weight loss (35%, 15/43). The majority of patients received thionamides (47%, 25/53). The clinical status after treatment was provided for 37 patients and it was improved in the majority of them (84%, 31/37). Graves’ disease is possibly a condition clinicians may expect to encounter in patients receiving COVID-19 vaccines. While the above adverse event is rare, considering the scarcity of available data in scientific literature, and causality is not yet confirmed, the increased awareness of clinicians and the early recognition of the disorder are important for the optimal management of these patients.
Keywords: Graves’ disease, thyroiditis, COVID-19, SARS–CoV–2, vaccines
Introduction
An outbreak of an atypical viral pneumonia initially reported at the end of 2019, was later declared a public health emergency of international concern in March 2020 (1, 2). The aetiology was a novel coronavirus strain called Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the cause of coronavirus disease 2019 (COVID-19), which has now disseminated across the globe with hundreds of millions affected (3, 4).
Different vaccines have been used widely against COVID-19 including: COMIRNATY (the COVID-19 mRNA vaccine BNT162b2 by BioNTech–Pfizer); COVID-19 Vaccine Moderna (mRNA-1273 by Moderna); VAXZEVRIA (ChAdOx1-nCoV19 by AstraZeneca-Oxford University); COVID-19 Vaccine Janssen (Ad26.COV2.S by Janssen); and CoronaVac COVID19 vaccine (Vero cell by Sinovac Biotech) (5, 6). Almost two thirds of the world population has now received at least one dose of a COVID-19 vaccine with 12 billion doses already administered worldwide (7).
Time has proven the aforementioned vaccines both safe and effective, with serious adverse events being rare, while providing 70-95% protection against severe disease (8–11). However, adverse reactions following vaccination remain inevitable, considering the extent and scale required to control seasonal outbreaks of COVID-19 infection (12–14). At present, patients experience numerous commonly reported adverse symptoms following COVID-19 vaccination, including muscle pain, fever, headache, nausea and vomiting. Beyond the most commonly presenting adverse effects post-COVID-19 vaccination, a diverse range of complaints and symptoms have been reported by patients, including also cases of immune-mediated adverse events (12–17). More recently though, there is an increasing number of reports pertained to thyroid disorders described in patients after the first or second doses of COVID-19 vaccination; however, they are not yet fully clarified.
Recent evidence suggests that viral effects of COVID-19 infection might be associated with thyroid function, possibly by contributing to the onset of thyroid disease or to the exacerbation of a pre-existing one (18–20). To date, COVID-19 vaccine administration has not been considered as a precipitating factor of thyroid dysfunction. In this study, we comprehensively examined the currently available literature to provide an overview of the reported cases of Graves’ disease following vaccination against SARS-CoV-2.
Methods
This review was reported based on the “Preferred Reporting Items for Systematic Reviews and Meta-Analyses” (PRISMA) guidelines.
Literature search
Two reviewers (KKT, PG) searched PubMed and Scopus library databases from inception until May 2022 independently. The search included the following terms: “(COVID 19 vaccin* OR SARS-COV2 vaccin*) AND (Graves’ disease OR Basedow Disease OR Exophthalmic Goiter OR Thyroiditis)”. No restrictions regarding study design, geographic region or language were applied. A manual search of references cited in the selected articles and published reviews were also ensued for undetected studies. Discrepancies in the literature search process were resolved by a third investigator (KSK).
Eligibility criteria
We included studies that provided data for new onset or exacerbation of Graves’ disease following COVID-19 vaccination with at least one dose. All study designs were considered eligible for inclusion. Review articles, abstracts submitted in conferences and non-peer reviewed sources were not eligible for inclusion. Studies on in vitro and animal models were excluded.
Data extraction and handling
In all studies, patient data was retrieved and handled by two authors (KKT, PG) who conducted the data extraction independently. We collected the following information: sex, age, comorbidities, type of vaccine, number of doses received, presenting symptoms after vaccination, history of COVID-19 infection, laboratory measurements, primary diagnosis, imaging findings, treatment, clinical outcome. Any disagreements were discussed and resolved by a third author (KSK).
Quality assessment
The studies were evaluated using the criteria established by the Task Force for Reporting Adverse Events of the International Society for Pharmacoepidemiology (ISPE) and the International Society of Pharmacovigilance (ISoP) (21). The assessment was based on the adequate reporting of 12 different elements namely: title, patient demographics, current health status, medical history, physical examination, patient disposition, drug identification, dosage, administration/drug reaction interface, concomitant therapies, adverse events, and discussion. The studies scored either 0 (absence of information) or 1 (containing the information) for every element.
Results
Study characteristics
The initial literature search yielded 188 publications. In the first screening 165 studies were excluded as irrelevant. After the exclusion phase, 21 studies (22–42) were eligible for the systematic review ( Figure 1 ). Ten of the studies were conducted in Asia, 6 in Europe, 4 in Americas, and 1 in Australia. In terms of design, 12 studies were case series and 9 were case reports ( Table 1 ).
Figure 1.
Prisma flowchart.
Table 1.
Characteristics of the included studies.
| Author,Year,Country | Case number | Age and Gender | Comorbidities | Previousthyroid disease(medications) | PreviousCOVID-19 infection | COVID-19 vaccine type and dose | New onset/relapse of Graves’ disease post vaccination | Main presenting symptoms | Days for the onset of symptoms | Treatment | Outcome |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Bostan, 2022 (38), Turkey |
Case 1 | 44 F | No | Graves’ Disease | No | CoronaVac 1st dose |
Relapse | • Sweating • Palpitation • Fatigue |
7 | Methimazole, Propranolol |
NA |
| Case 2 | 49 M | No | Graves’ Disease | No | COMIRNATY 2nd dose |
Relapse | • Sweating • Palpitations • Tremor |
30 | Methimazole, Propranolol |
Improvement after 4 weeks |
|
| Case 3 | 31 F | Breast cancer | Graves’ Disease | No | COMIRNATY 1st dose |
Relapse | • Sweating • Hot flushes • Weakness |
21 | Methimazole, Propranolol |
Improvement after 5 weeks |
|
| Case 4 | 53 F | No | Hashimoto’s thyroiditis (On levothyroxine) |
Yes | COMIRNATY 1st dose |
New onset | • Sweating • Palpitations • Weight loss |
7 | Propranolol | Improvement after 8 weeks |
|
| Case 5 | 51 F | Diabetes, Hypertension |
No | NA | COMIRNATY 2nd dose |
New onset | • Right eye proptosis • Irritation • Dryness |
4 | Methimazole, Propranolol |
Thyroidectomy after 4 months |
|
| Case 6 | 47 F | Obesity | No | No | COMIRNATY 1st dose |
New onset | • Sweating • Palpitations |
5 | Methimazole, Propranolol |
Improvement after 4 weeks |
|
| Case 7 | 46 M | No | No | No | COMIRNATY 2nd dose |
New onset | • Sweating • Emotional liability • Palpitations • Weight loss |
21 | Methimazole, Propranolol |
Improvement after 4 weeks |
|
| Chee, 2022 (39), Singapore |
Case 1 | 33 F | NA | No | No | mRNA vaccine* 1st dose |
New onset | NA | 7 | Carbimazole, Propranolol | Improvement after 4 weeks |
| Case 2 | 37 F | NA | No | No | mRNA vaccine* 1st dose |
New onset | NA | 7 | Carbimazole, Propranolol | Improvement after 32 days |
|
| Case 3 | 37 F | NA | No | No | mRNA vaccine* 2nd dose |
New onset | NA | 21 | Carbimazole, Propranolol | Improvement after 53 days |
|
| Case 4 | 34 F | NA | No | No | mRNA vaccine* 1st dose |
New onset | NA | 26 | Carbimazole, Propranolol | Improvement after 58 days |
|
| Case 5 | 33 F | NA | No | No | mRNA vaccine* 2nd dose |
New onset | NA | 9 | Carbimazole, Propranolol | Improvement after 64 days |
|
| Case 6 | 43 F | NA | No | No | mRNA vaccine* 2nd dose |
New onset | NA | 13 | Carbimazole | Improvement after 29 days |
|
| Case 7 | 59 M | NA | Graves’ Disease | No | mRNA vaccine* 1st dose |
Relapse | NA | 21 | Carbimazole | Still not in remission | |
| Case 8 | 74 F | NA | Graves’ Disease | No | mRNA vaccine* 2nd dose |
Relapse | •Asymptomatic | 11 | Carbimazole | NA | |
| Case 9 | 25 F | NA | Graves’ Disease | No | mRNA vaccine* 2nd dose |
Relapse | •Asymptomatic | 31 | Carbimazole | Improvement after 123 days |
|
| Case 10 | 41 F | NA | Graves’ Disease | No | mRNA vaccine* 2nd dose |
Relapse | NA | 28 | Carbimazole | Improvement after 31 days |
|
| Case 11 | 24 F | NA | Graves’ Disease | No | mRNA vaccine* 2nd dose |
Relapse | •Asymptomatic | 63 | Carbimazole | Improvement after 42 days |
|
| Case 12 | 22 F | NA | Graves’ Disease | No | mRNA vaccine* 1st dose |
Relapse | NA | 5 | Carbimazole, Propranolol |
Improvement after 178 days |
|
| Chua, 2022 (37), Singapore |
Case 1 | 41 M | NA | Graves’ Disease (On carbimazole) |
NA | COVID-19 Vaccine Moderna 1st dose |
Relapse | •Tremor •Palpitations |
5 | Carbimazole | NA |
| Case 2 | 45 F | NA | No | NA | COMIRNATY 1st dose |
New onset | •Chest tightness •Palpitations |
4 | Carbimazole | NA | |
| Di Fillipo, 2021 (35), Italy |
Case 1 | 32 M | No | No | NA | VAXZEVRIA 2nd dose |
New onset | •Anxiety •Tachycardia •Palpitations |
10 | Propranolol, Thiamazole, Propylthiouracil (switched from thiamazole) | Improvement after 3 months |
| Case 2 | 35 M | No | No | NA | VAXZEVRIA 1st dose |
New onset | •Headache •Nausea •Asthenia •Palpitations •Tachycardia •Opthalmopathy |
5 | Thiamazole, Propranolol | Improvement after 3 months |
|
| Goblirsch, 2021, (23) USA |
Case 1 | 71 F | Breast cancer, Struma ovarii |
Multinodular goitre | No | COMIRNATY 2nd dose |
New onset | •Palpitations •Fever •Sweating •Dyspnoea •Leg swelling •Dizziness •Nausea •Diarrhoea •Abdominal pain •Tremor |
14 | Methimazole, Atenolol |
Improvement of symptoms but moderate to severe Graves opthalmopathy |
| Hamouche, 2021, (25) | Case 1 | 32 M | No | No | Yes | COMIRNATY 1st dose |
New onset | •Dry cough •Low-grade fever •Fatigue •Palpitations •Insomnia •Tremor •Irritability •Diaphoresis •Dyspnoea |
10 | Methimazole, Propranolol, Prednisone |
Improvement after 6 weeks |
| Lee, 2021, (41) South Korea |
Case 1 | 46 F | NA | NA | NA | VAXZEVRIA 1st dose |
New onset | •Chest pain •Dyspnoea |
1 | NA | NA |
| Case 2 | 73 F | NA | NA | NA | VAXZEVRIA 2nd dose |
New onset | •Weight loss •Dyspnoea |
14 | NA | NA | |
| Case 3 | 39 M | NA | Graves’ Disease | NA | COVID-19 Vaccine Janssen 1st dose |
New onset | •Fever •Neck pain |
14 | NA | NA | |
| Case 4 | 34 M | NA | NA | NA | COVID-19 Vaccine Janssen 1st dose |
NA | •Weight loss •Palpitations |
14 | NA | NA | |
| Lui, 2021, (26) China |
Case 1 | 32 F | No | Hypothyroidism (On thyroxine) |
No | COMIRNATY 2nd dose |
New onset | •Palpitations | 38 | Carbimazole, Propranolol | Improvement |
| Oguz, 2021, (36) Turkey |
Case 1 | 40 F | No | No | NA | COMIRNATY 3rd dose |
New onset | NA | 2 | Methimazole | Not in remission yet |
| Case 2 | 29 M | No | No | NA | COMIRNATY 1st dose |
New onset | NA | 15 | Nil | Improvement after 10 weeks |
|
| Case 3 | 43 F | Ankylosing spondilitis | Multinodular goiter | NA | COMIRNATY 3rd dose |
New onset | NA | 9 | Methimazole | Not in remission yet | |
| Case 4 | 43 F | Diabetes insipidus | Autoimmune thyroiditis | NA | COMIRNATY 1st dose |
New onset | NA | 14 | Discontinue Levothyroxine | Hypothyroidism | |
| Case 5 | 34 F | No | No | NA | CoronaVac 1st dose |
New onset | NA | 150 | Methimazole, Prednisolone | Not in remission | |
| Patrizio, 2021, (30) Italy |
Case 1 | 52 M | Diabetes mellitus, Vitiligo vulgaris |
No | No | COMIRNATY 2nd dose |
New onset | •Weight loss •Fatigue |
28 | Methimazole, Atenolol, Insulin analogues |
Improvement |
| Pierman, 2021, (29) Belgium |
Case 1 | 34 F | NA | Graves’ disease (On thiamazole) |
NA | COMIRNATY 1st dose |
Relapse | •Ophthalmopathy •Tremor •Sweating •Thermophobia •Dyspnoea •Weight loss |
10 | Thiamazole | NA |
| Pla Peris, 2022, (22) Spain |
Case 1 | 71 F | NA | NA | NA | COMIRNATY | NA | •Weight loss •Fatigue •Atrial fibrillation |
60 | Methimazole | NA |
| Case 2 | 42 F | NA | NA | NA | COMIRNATY | NA | •Weight loss •Fatigue •Palpitations |
10 | Methimazole | NA | |
| Case 3 | 54 F | NA | NA | NA | COVID-19 Vaccine Moderna |
NA | •Weight loss •Fatigue •Palpitations |
10 | Methimazole | NA | |
| Case 4 | 46 F | NA | NA | NA | COMIRNATY | NA | •Weight loss •Fatigue •Palpitations •Irritability |
50 | Methimazole | NA | |
| Case 5 | 69 F | NA | NA | NA | COMIRNATY | NA | •Neck pain •Fever •Weight loss •Palpitations •Tremor |
10 | Methimazole, NSAID |
NA | |
| Pujol, 2021, (27) Spain |
Case 1 | 38 F | Mental retardation, Schizophrenia |
No | NA | COMIRNATY 1st dose |
New onset | •Irritation •Insomnia •Sweating |
12 | Methimazole | NA |
| Raven, 2021, (40) Australia |
Case 1 | 35 F | NA | No | NA | VAXZEVRIA 1st dose |
New onset | •Tremor •Palpitations •Hyperphagia •Thermophobia |
5 | Carbimazole | NA |
| Shih, 2022, (42) Taiwan |
Case 1 | 39 F | NA | No | NA | COVID-19 Vaccine Moderna |
New onset | •Tremor •Palpitations |
14 | Carbimazole | NA |
| Case 2 | 59 F | NA | No | NA | VAXZEVRIA | New onset | •Dizziness •Palpitations |
14 | Carbimazole | NA | |
| Case 3 | 44 F | NA | No | NA | VAXZEVRIA | New onset | •Tremor •Thermophobia •Weight loss |
4 | Carbimazole | NA | |
| Sriphrapradang, 2021 (I), (31) Thailand |
Case 1 | 70 M | NA | NA | No | VAXZEVRIA 2nd dose |
NA | •Dyspnoea •Myalgia •Palpitations •Poor appetite •Weight loss |
2 | Methimazole | NA |
| Sriphrapradang, 2021 (II), (32) Thailand |
Case 1 | 30 F | NA | Graves’ Disease (On methimazole) |
NA | VAXZEVRIA 3rd dose |
Exacerbation | •Palpitations •Weight loss |
4 | Methimazole | Improvement after 30 days |
| Vera- Lastra, 2021, (34) Mexico |
Case 1 | 40 F | Hypertension | No | NA | COMIRNATY | New onset | •Nausea •Vomiting •Fatigue •Insomnia •Palpitations |
2 | Thiamazole, Diltiazem, Ivabradine |
Improvement |
| Case 2 | 28 F | No | No | NA | COMIRNATY | New onset | •Anxiety •Insomnia •Palpitations •Tremor |
3 | Thiamazole, Propranolol | Improvement | |
| Weintraub, 2021, (24) USA |
Case 1 | 38 F | NA | NA | NA | COMIRNATY 1st dose |
New onset | •Tachycardia •Fever •Abdominal pain |
5 | Methimazole, Propranolol |
Improvement after 3 months |
| Case 2 | 63 F | NA | NA | NA | COVID-19 Vaccine Moderna 1st dose |
New onset | •Pruritic rash | 7 | Nil | Improvement | |
| Case 3 | 30 M | NA | NA | NA | COMIRNATY 2nd dose |
New onset | •Weight loss •Palpitations •Tremor •Irritability |
28 | Methimazole, Atenolol |
Improvement after 6 weeks |
|
| Yamamoto, 2021, (28), Japan |
Case 1 | 64 F | Colorectal cancer, Diabetes mellitus, Obesity |
NA | No | COMIRNATY 1st dose |
New onset | •Fever •Fatigue •Dyspnoe •Decreased urine output •Leg swelling •Palpitations |
6 | Thiamazole, Potassium iodine, Corticosteroids, Furosemide, Carvedilol |
Improvement after 11 days |
| Zettinig, 2021, (33) Austria |
Case 1 | 71 F | Hemithyroidectomy | Grave’s disease | NA | COMIRNATY 2nd dose |
Relapse | •Palpitations | NA | Thyreostatic treatment | Improvement |
| Case 2 | 46 M | NA | No | NA | COMIRNATY 1st dose |
New onset | •Asymptomatic | 35 | Thyreostatic treatment | Improvement |
F, Female; M, Male; NA, Not available; NSAID, Non-steroidal anti-inflammatory drugs.
*Brand not specified.
We identified a total of 57 cases of Graves’ disease following COVID-19 vaccination. Fourteen participants were males (25%, 14/57) and 43 (75%, 43/57) were females with a mean age of 44.3 years (median: 41.5, interquartile range: 34-51.5). Data regarding medical history was provided for 30 cases and half of them had no past medical history (50%, 15/30) with two patients having hypothyroidism before vaccination (66%, 2/30). From the included patients 37 (74%, 37/50) were characterised as new-onset, 12 (26%, 12/50) as relapse and one (2%, 2/50) as exacerbation. The mean age of individuals with Graves’ disease relapse was 42.9 (median: 41, interquartile range: 28-59) with the majority of them receiving mRNA vaccines (92%, 11/12).
For most of the patients (58%, 33/57) data regarding COVID-19 infection before or at the time of Graves’ diagnosis was not provided. Among the remaining patients only 2 were previously infected with SARS-CoV-2. In 12 patients, vaccine brand was not mentioned (21%, 12/57). The majority of the patients received COMIRNATY (64%, 29/45), followed by VAXZEVRIA (18%, 8/45), while a fraction of participants received COVID-19 Vaccine Moderna (9%, 4/45), COVID-19 Vaccine Janssen (4%, 2/45) and CoronaVac (4%, 2/45).
Data regarding the day of the onset of symptoms was provided for 56 cases. On average, the symptoms developed 14.8 days (median: 10, interquartile range: 5-21) after the administration of the vaccine irrespective of the dose. A significant proportion of patients developed symptoms after the 1st dose (55%, 26/47), followed by the 2nd dose (38%, 18/47). Only 3 cases (6%, 3/47) developed symptoms after the 3rd dose.
Data regarding symptomatology was provided for 43 cases. The most common symptom was palpitations (63%, 27/43) followed by weight loss (35%, 15/43). Other common symptoms included tremor (25%, 11/43) and fatigue/weakness (23%, 10/43). Almost all patients had positive thyrotropin receptor antibody (TRAb) or Thyroid stimulating immunoglobin (TSI) (96%, 55/57) except for two people who had imaging findings consistent with Graves’ disease (3%, 2/57). Thyroid stimulating hormone (TSH) levels were provided for 54 patients and they were decreased in all of them (100%, 54/54).
Thyroid ultrasound data was provided for 36 patients. Twenty-four of them had increased vascularity (67%, 24/36) ( Table 2 ). Data regarding thyroid scintigraphy was provided for only 12 cases, with the majority having findings of increased diffuse uptake consistent with Graves’ disease (75%, 9/12). Data regarding treatment was available for 53 cases. Most of them received thionamides (47%, 25/53). The clinical status after treatment was provided for 37 patients and it was improved in the majority of them (84%, 31/37).
Table 2.
Laboratory and imaging findings of the reported cases.
| Author,Year,Country | Case number | Thyroid function tests | Normal references for thyroid function tests | Thyroid autoantibodies | Thyroidultrasound | Thyroid scintigraphy |
|---|---|---|---|---|---|---|
| Bostan, 2022, (38) Turkey |
Case 1 | TSH: < 0.01 mIU/L | 0.27–4.2 mIU/L | •TRAb: 12.18 IU/L •TSI: NA •Anti-TPO:284 IU/ml •Anti-Tg:119 IU/ml |
Hypoechoic areas, increased vascularity in a ‘Thyroid inferno’ pattern | NA |
| FT3: 9.65 ng/L | 2–4.4 ng/L | |||||
| T3:NA | NA | |||||
| FT4: 2.67 ng/dL | 0.93–1.7 ng/dL | |||||
| Case 2 | TSH<0.01 mIU/L | 0.27–4.2 mIU/L | •TRAb: 3.01 IU/L •TSI: NA •Anti-TPO:435 IU/ml •Anti-Tg:236 IU/ml |
Increased vascularity | NA | |
| FT3: 13.50 ng/L | 2–4.4 ng/L | |||||
| T3: NA | NA | |||||
| FT4:3.86 ng/dL | 0.93–1.7 ng/dL | |||||
| Case 3 | TSH: <0.01 mIU/L | 0.27–4.2 mIU/L | •TRAb: 19.30 IU/L •TSI: NA •Anti-TPO: 325 IU/ml •Anti-Tg:11 IU/ml |
Increased vascularity | NA | |
| FT3: 21.70 ng/L | 2–4.4 ng/L | |||||
| T3: NA | NA | |||||
| FT4: 7.77 ng/dL | 0.93–1.7 ng/dL | |||||
| Case 4 | TSH: <0.01 mIU/L | 0.27–4.2 mIU/L | •TRAb: 17.84 IU/L •TSI: NA •Anti-TPO: 55 IU/ml •Anti-Tg: 1197 IU/ml |
Normal thyroid gland size, highly heterogeneous parenchyma, increased vascularity | Increased diffuse activity uptake in both thyroid lobes | |
| FT3: 8.83 ng/L | 2–4.4 ng/L | |||||
| T3: NA | NA | |||||
| FT4: 4.01 ng/dL | 0.93–1.7 ng/dL | |||||
| Case 5 | TSH: <0.01 mIU/L | 0.27–4.2 mIU/L | •TRAb: 5.04 IU/L •TSI: NA •Anti-TPO: 12.4 IU/ml •Anti-Tg: 18.2 IU/ml |
Enlarged thyroid with multinodular goiter | Hypoactive multinodular hyperplasic thyroid gland | |
| FT3: 12.6 ng/dl | 2–4.4 ng/L | |||||
| T3: NA | NA | |||||
| FT4: 3.72 ng/dL | 0.93–1.7 ng/dL | |||||
| Case 6 | TSH: <0.01 mIU/L | 0.27-4.2mIU/L | •TRAb: 22.74 IU/L •TSI: NA •Anti-TPO:11.2 IU/ml •Anti-Tg: 320 IU/ml |
Diffuse hypoechoic areas in the bilaterally enlarged thyroid gland and increased vascularity | NA | |
| FT3: 11.0 ng/dL | 2-4.4 ng/dL | |||||
| T3: NA | NA | |||||
| FT4: 3.32 ng/dL | 0.93-1.7 ng/dL | |||||
| Case 7 | TSH: <0.01 mIU/L | 0.27-4mIU/L | •TRAb: 9.10 IU/L •TSI: NA •Anti-TPO: 146 IU/ml •Anti-Tg: 334 IU/ml |
Diffuse hypoechoic areas in the bilaterally enlarged thyroid gland and increased vascularity in a ‘Thyroid inferno’ pattern | NA | |
| FT3: 25.3 ng/L | 2-4.4 ng/L | |||||
| T3: NA | NA | |||||
| FT4: 7.7 ng/dL | 0.93-1.7 ng/L | |||||
| Chees, 2022, (39) Singapore |
Case 1 | TSH: 0.01 mIU/L | 0.45-4.5 mIU/L | •TRAb: 7.3IU/L* •TSI: NA •Anti-TPO: NA •Anti-TG: NA |
NA | NA |
| FT3: NA | NA | |||||
| T3: NA | NA | |||||
| FT4: 45 pmol/L | 8-16 pmol/L | |||||
| Case 2 | TSH: <0.01 mIU/L | 0.45-4.5mIU/L | •TRAb: 3.8 IU/ml* •TSI: NA •Anti-TPO: NA •Anti-TG: NA |
NA | NA | |
| FT3: NA | NA | |||||
| T3: NA | NA | |||||
| FT4: 60 pmol/L | 8-16 pmol/L | |||||
| Case 3 | TSH: 0.01 mIU/L | 0.45-4.5 mIU/L | •TRAb: 11.2 IU/ml* •TSI: NA •Anti TPO: NA •Anti-TG: NA |
NA | NA | |
| FT3: 23.8 pmol/L | 3.5-6 pmol/L | |||||
| T3: NA | NA | |||||
| FT4: 68 pmol/L | 8-16 pmol/L | |||||
| Case 4 | TSH: <0.01 mIU/L | 0.45-4.5 mIU/L | •TRAb: 32 IU/ml* •TSI: NA •Anti-TPO: NA •Anti-TG: NA |
NA | NA | |
| FT3: NA | NA | |||||
| T3: NA | NA | |||||
| FT4: 29 pmol/L | 8-16 pmol/L | |||||
| Case 5 | TSH: <0.01 mIU/L | 0.45-4.5mIU/L | •TRAb: 4.6 IU/ml* •TSI: NA •Anti-TPO: NA •Anti-TG: NA |
NA | NA | |
| FT3: NA | NA | |||||
| T3: NA | NA | |||||
| FT4: 29 pmol/L | 8-16 pmol/L | |||||
| Case 6 | TSH: <0.01 mIU/L | 0.45-4.5 mIU/L | •TRAb: 6.2 IU/ml* •TSI: NA •Anti-TPO: NA •Anti-TG: NA |
NA | NA | |
| T3: NA | 3.5-6 pmol/L | |||||
| FT3: >40 pmol/L | NA | |||||
| FT4: 70 pmol/L | 8-16 pmol/L | |||||
| Case 7 | TSH: <0.01 | 0.45-4.5 mIU/L | •TRAb: 12.8 IU/ml* •TSI: NA •Anti-TPO: NA •Anti-TG: NA |
NA | NA | |
| FT3: NA | 3.5-6 pmol/L | |||||
| T3: NA | NA | |||||
| FT4: 49 pmol/L | 8-16 pmol/L | |||||
| Case 8 | TSH: 0.02 mIU/L | 0.45-4.5 mIU/L | •TRAb: 6.2 IU/ml* •TSI: NA •Anti-TPO: NA •Anti-TG: NA |
NA | NA | |
| FT3: NA | 3.5-6 pmol/L | |||||
| T3: NA | NA | |||||
| FT4: 14 pmol/L | 8-16 pmol/L | |||||
| Case 9 | TSH: 0.02 mIU/L | 0.45-4.5 mIU/L | •TRAb: 2.9 IU/ml* •TSI: NA •Anti-TPO: NA •Anti-TG: NA |
NA | NA | |
| FT3: 6.3 pmol/L | 3.5-6 pmol/L | |||||
| T3: NA | NA | |||||
| FT4: 15 pmol/L | 8-16 pmol/L | |||||
| Case 10 | TSH: 0.01 mIU/ml | 0.45-4.5 mIU/L | •TRAb: 3.9 IU/ml* •TSI: NA •Anti-TPO: NA •Anti-TG: NA |
NA | NA | |
| FT3: NA | 3.5-6 pmol/L | |||||
| T3: NA | NA | |||||
| FT4: 20 pmol/L | 8-16 pmol/L | |||||
| Case 11 | TSH: 0.01 mIU/ml | 0.45-4.5 mIU/L | •TRAb: 2.4 IU/ml* •TSI: NA •Anti-TPO: NA •Anti-TG: NA |
NA | NA | |
| FT3: NA | 3.5-6 pmol/L | |||||
| T3: NA | NA | |||||
| FT4: 20 pmol/L | 8-16 pmol/L | |||||
| Case 12 | TSH: 0.01 mIU/L | 0.45-4.5 mIU/L | •TRAb: 5.8 IU/ml* •TSI: NA •Anti-TPO: NA •Anti-TG: NA |
NA | NA | |
| FT3: >40 pmol/L | 3.5-6 pmol/L | |||||
| T3: NA | NA | |||||
| FT4: 70 pmol/L | 8-16 pmol/L | |||||
| Chua, 2022, (37) Singapore |
Case 1 | TSH: <0.01 mIU/L | 0.7-4.28 mIU/L | •TRAb: 3.85 IU/L**
•TSI: NA •Anti-TPO: NA •Anti-TG: NA |
NA | NA |
| FT3: NA | NA | |||||
| T3: NA | NA | |||||
| FT4: 48.2 pmol/L | 12.7-20.3 pmol/L | |||||
| Case 2 | TSH: <0.005 mIU/L | 0.7-4.28 mIU/L | •TRAb: 5.75 IU/L**
•TSI: NA •Anti-TPO: 0.3 IU/ml† •Anti-TG: NA |
Heterogeneous thyroid gland with increased vascularity, a few sub-centimetre solid and cystic nodules | NA | |
| FT3: NA | NA | |||||
| T3: NA | NA | |||||
| FT4: 45.1 pmol/L | 12.7-20.3 pmol/L | |||||
| Di Filippo, 2021, Italy |
Case 1 | TSH:0.005 uIU/mL | NA | •TRAb: 7.9 IU/L***
•TSI: NA •Anti TPO: NA •Anti Tg: NA |
Gland enlargement with pseudonodules, increased vascularity | NA |
| FT3: 7.9 pg/ml | 2-4.4 pg/ml | |||||
| T3: NA | NA | |||||
| FT4: 2.96 ng/dL | 0.6-1.12 ng/dL | |||||
| Case 2 | TSH: <0.004 uIU/mL | NA | •TRAb:3.2 IU/L***
•TSI: NA •Anti TPO: NA •Anti Tg: NA |
Gland enlargement, increased vascularity | NA | |
| FT3: NA | 2-4.4 pg/ml | |||||
| T3: NA | NA | |||||
| FT4: 4.96 ng/dL | 0.6-1.12 ng/dL | |||||
| Goblirsch, 2021, (23) USA |
Case 1 | TSH: <0.02 IU/mL | 0.35-2 IU/mL | •TRAb: NA •TSI: 347% •Anti TPO: 8.9 IU/mL† •Anti Tg: NA |
Multinodular disease | NA |
| FT3: NA | FT3: NA | |||||
| T3: 5.3 ng/mL | 0.8-2.8 ng/mL | |||||
| FT4: 7.2 ng/dL | 0.9-1.7 ng/dL | |||||
| Hamouche, 2021, (25) USA |
Case 1 | TSH: <0.005 uIU/mL | 0.282-4 uIU/mL | •TRAb: NA •TSI: 200%‡ •Anti TPO: 119 IU/mL •Anti Tg: 53§ |
Heterogeneous thyroid with underlying micronodules suggestive of thyroiditis. | 72% homogeneous uptake |
| FT3: NA | NA | |||||
| T3: 397 ng/dL | 69-154 ng/dL | |||||
| FT4: 5.41 ng/d | 0.84-1.62 ng/dL | |||||
| Lee, 2021,(41) South Korea |
Case 1 | TSH: 0.010 IU/mL | 0.55-4.78 IU/mL | •TRAb: 6.42 IU/L**
•TSI: NA •Anti TPO: 77.72 IU/ml •Anti Tg: 137.5 IU/ml |
Increased vascularity | NA |
| FT3: NA | NA | |||||
| T3: NA | NA | |||||
| FT4: 33.92 ng/dL | 11.5-22.7 ng/dL | |||||
| Case 2 | TSH: <0.008 IU/mL | 0.55-4.78 IU/mL | •TRAb: 6.1 IU/L**
•TSI: NA •Anti TPO: 43.3 IU/ml •Anti Tg: NA |
Increased vascularity | NA | |
| FT3: NA | NA | |||||
| T3: NA | NA | |||||
| FT4: 73.80 ng/dL | 11.5-22.7 ng/dL | |||||
| Case 3 | TSH: <0.012 IU/mL | 0.55-4.78 IU/mL | •TRAb: 2.9 IU/L**
•TSI: NA •Anti TPO: <15 IU/ml •Anti Tg: 295.5 IU/ml |
Diffuse goiter with ill-defined hypoechoic lesion | NA | |
| FT3: NA | NA | |||||
| T3: NA | NA | |||||
| FT4: 36.98 ng/dL | 11.5-22.7 ng/dL | |||||
| Case 4 | TSH: <0.008 IU/mL | 0.55-4.78 IU/mL | •TRAb: 4.24 IU/L**
•TSI: NA •Anti TPO: NA •Anti Tg: NA |
Increased vascularity | NA | |
| FT3: NA | NA | |||||
| T3: NA | NA | |||||
| T4: 26.61 ng/dL | 11.5-22.7 ng/dL | |||||
| Lui, 2021, (26) China |
Case 1 | TSH: <0.02 mIU/L | 0.47-4.68 mIU/L | •TRAb: NA •TSI: 420% •Anti TPO: NA •Anti Tg: NA |
Heterogeneous thyroid echogenicity with increased vascularity | Diffuse markedly increased uptake over both lobes, increased blood flow |
| FT3: 30.5 pmol/L | 4.26-8.1 pmol/L | |||||
| T3: NA | NA | |||||
| FT4: 66.6 pmol/L | 10-28.2 pmol/L | |||||
| Oguz, 2021, (36) Turkey |
Case 1 | TSH: <0.015 mIU/L | 0.38-5.33 mIU/L | •TRAb: 10.3 IU/mL •TSI: NA •Anti TPO: 195.7 IU/mL† •Anti Tg: 7.1 IU/mL§§ |
Diffuse hyperplasia, increased vascularity | Diffusely increased radiotracer uptake |
| FT3: 8.79 pmol/L | 3.8-6 pmol/L | |||||
| T3: NA | NA | |||||
| FT4: 27.92 pmol/L | 7.86-14.41 pmol/L | |||||
| Case 2 | TSH: <0.0015 mIU/L | 0.38-5.33 mIU/L | •TRAb: 0.97 IU/mL •TSI: NA •Anti TPO: 0.7 IU/mL† •Anti Tg<-0.9 IU/mL§§ |
Diffuse hyperplasia, increased vascularity | 24-hour RAIU: 27% | |
| FT3: 7.19 pmol/L | 3.8-6 pmol/L | |||||
| T3: NA | NA | |||||
| FT4: 12.15 pmol/L | 7.86-14.41 pmol/L | |||||
| Case 3 | TSH: 0.015 mIU/L | 0.38-5.33 mIU/L | •TRAb: 0.25 IU/mL •TSI: NA •Anti TPO: 0.8IU/mL† •Anti Tg: 1.8 IU/mL§§ |
Diffuse hyperplasia, increased vascularity | 24-hour RAIU: 61% | |
| FT3: 11 pmol/L | 3.8-6 pmol/L | |||||
| T3: NA | NA | |||||
| FT4: 33.1 pmol/L | 7.86-14.41 pmol/L | |||||
| Case 4 | TSH: 0.01 mIU/L | 0.38-5.33 mIU/L | •TRAb: 1.9 IU/mL •TSI: NA •Anti TPO: 196 IU/mL† •Anti Tg: 167 IU/mL§§ |
Diffuse hyperplasia, increased vascularity | 24-hour RAIU: 23% | |
| FT3: 7.8 pmol/L | 3.8-6 pmol/L | |||||
| T3: NA | NA | |||||
| FT4: 25.5 pmol/L | 7.86-14.41 pmol/L | |||||
| Case 5 | TSH: 0.0 mIU/L | 0.38-5.33 mIU/L | •TRAb: 3 IU/mL •TSI: NA •Anti TPO: 1.2 IU/mL† •Anti Tg<0/9 IU/mL§§ |
NA | 24-hour RAIU 39% | |
| FT3: 10.54 mIU/L | 3.8-6 pmol/L | |||||
| T3: NA | NA | |||||
| FT4: 31.65 pmol/L | 7.86-14.41 pmol/L | |||||
| Patrizio, 2021, (30) Italy |
Case 1 | TSH: <0.004 mIU/L | 0.4–4.00 mIU/L | •TRAb: 6.48 IU/L •TSI: NA •Anti TPO: 21 IU/mL† •Anti Tg: 30 IU/mL§§§ |
Enlarged thyroid gland with heterogeneous echotexture, increased vascularity | NA |
| FT3: 15 ng/dL | 2.7–5.7 ng/L | |||||
| T3: NA | NA | |||||
| FT4: 5.56 ng/dL | 0.7–1.7 ng/dL | |||||
| Pierman, 2021, (29) Belgium |
Case 1 | TSH: 0.01 mIU/L | 0.4-2.75 mIU/L | •TRAb: >40 IU/L****
•TSI: NA •Anti TPO: NA •Anti Tg: NA |
NA | NA |
| FT3: 22.09 pmol/L | 3-6.5 pmol/L | |||||
| T3: NA | NA | |||||
| FT4: 2.54 ng/dL | 0.75-1.6 ng/dL | |||||
| Pla Peris, 2022, (22) Spain |
Case 1 | TSH: <0.005 mUI/L | 0.38-5.33 mUI/L | •TRAb: 3.6 U/L •TSI: NA •Anti TPO: 30 U/ml† •Anti Tg: <0.9U/ml§§ |
Enlarged thyroid, increased vascularity | Diffuse markedly increased uptake over both lobes |
| FT3: NA | NA | |||||
| T3: NA | NA | |||||
| FT4: 2.3 ng/dL | 0.54-1.24 ng/dL | |||||
| Case 2 | TSH: <0.005 mUI/L | 0.38-5.33 mUI/L | •TRAb: 4.39 U/L •TSI: NA •Anti TPO: NA •Anti Tg: 2.5 U/ml§§ |
Enlarged thyroid, increased vascularity | Diffuse markedly increased uptake over both lobes | |
| FT3: NA | NA | |||||
| T3: NA | NA | |||||
| FT4: 2.9 ng/dL | 0.54-1.24 ng/dL | |||||
| Case 3 | TSH: <0.005 mUI/L | 0.38-5.33 mUI/L | •TRAb: 5.1 U/L •TSI: NA •Anti TPO: 30 U/ml† •Anti Tg: 55 U/ml§§ |
Enlarged thyroid, increased vascularity | NA | |
| FT3: NA | NA | |||||
| T3: NA | NA | |||||
| FT4: 4.7 ng/dL | 0.54-1.24 ng/dL | |||||
| Case 4 | TSH: <0.005 mUI/L | 0.38-5.33 mUI/L | •TRAb: 3.2 U/L •TSI: NA •Anti TPO: 60 U/ml† •Anti Tg: 90 U/ml§§ |
Enlarged thyroid, increased vascularity | NA | |
| FT3: NA | NA | |||||
| T3: NA | NA | |||||
| FT4: 4.2 ng/dL | 0.54-1.24 ng/dL | |||||
| Case 5 | TSH: <0.005 mUI/L | 0.38-5.33 mUI/L | •TRAb: 3.8 U/L •TSI: NA •Anti TPO: <0.5 U/ml† •Anti Tg: 0.9 U/ml§§ |
NA | NA | |
| FT3: NA | NA | |||||
| T3: NA | NA | |||||
| FT4: 1.8 ng/dL | 0.54-1.24 ng/dL | |||||
| Pujol, 2021, (27) Spain |
Case 1 | TSH: <0.001 μIU/mL | 0.35-4.95 μIU/mL | •TRAb: 12.54 IU/ml •TSI: 12.54 IU/ml‡‡ •Anti TPO: 3303.7 IU/ml†† •Anti Tg: 36.57§§ |
Diffuse decrease in echogenicity with some echogenic septum, increased vascularity | NA |
| FT3: 7.46 pg/mL | 1.58-3.91 pg/mL | |||||
| T3: NA | NA | |||||
| FT4: 2.01 ng/dL | 0.7-1.48 ng/dL | |||||
| Raven, 2021, (40) Australia |
Case 1 | TSH: < 0.02 mIU/L | 0.5-4.0 mIU/L | •TRAb: NA •TSI: 24 IU/ml •Anti TPO: > 1300 IU/ml •Anti Tg: 33 IU/ml |
Diffusely heterogeneous thyroid, increased vascularity | NA |
| FT3: > 30 pmol/L | 3.5-6 pmol/L | |||||
| T3: NA | NA | |||||
| FT4: 64 pmol/L | 10-20 pmol/L | |||||
| Shih, 2022, (42) Taiwan |
Case 1 | TSH: <0.0038 mIU/L | 0.35-4.94 mIU/L | •TRAb: 42.4%*****
•TSI: NA •Anti TPO: 64.58 IU/ml †† •Anti-Tg: <3 IU/ml§§§§ |
NA | NA |
| FT3: NA | NA | |||||
| T3: NA | NA | |||||
| FT4: 1.29 ng/dL | 0.7-1.48 ng/dL | |||||
| Case 2 | TSH: 0.0091 mIU/L | 0.35-4.94 mIU/L | •TRAb: 68.7%*****
•TSI: NA •Anti TPO<3 IU/mL†† •Anti-Tg: 1494.78IU/mL§§§§ |
NA | NA | |
| FT3: NA | NA | |||||
| T3: NA | NA | |||||
| FT4: 1.06 ng/dL | 0.7-1.48 ng/dL | |||||
| Case 3 | TSH<0.0038 mIU/L | 0.35-4.94 mIU/L | •TRAb: 80.9%*****
•TSI: NA •Anti TPO: 206.64<3 IU/mL†† •Anti-Tg: 2904.39 IU/mL§§§§ |
NA | NA | |
| FT3: NA | NA | |||||
| T3: NA | NA | |||||
| FT4: 0.83 ng/dL | 0.7-1.48 ng/dL | |||||
| Sriphrapradang, 2021 (I), (31) Thailand |
Case 1 | TSH: <0.0036 mIU/L | 0.35-4.94 mIU/L | •TRAb: 3.23 IU/ml •TSI: NA •Anti TPO: NA •Anti Tg: NA |
NA | NA |
| FT3: >20 pg/mL | 1.88–3.18 pg/mL | |||||
| T3: NA | NA | |||||
| FT4: 3.19 ng/dL | 0.7–1.48 ng/dL | |||||
| Sriphrapradang, 2021 (II), (32) Thailand |
Case 1 | TSH: 0.006 mIU/L | 0.35-4.94 mIU/L | •TRAb: 13.4 IU/ml •TSI: NA •Anti TPO: NA •Anti Tg: NA |
NA | NA |
| FT3: 3.21 pg/mL | 1.88–3.18 pg/mL | |||||
| T3: NA | NA | |||||
| FT4: 1.29 ng/dL | 0.7–1.48 ng/dL | |||||
| Vera- Lastra, 2021, (34) Mexico |
Case 1 | TSH: <0.001 μgUi/mL | 0.27-4.4 μgUi/mL | •TRAb: 16.56 IU/ml •TSI: 380% •Anti TPO: 3405 IU/ml†† •Anti Tg: 210 IU/ml§ |
NA | NA |
| FT3: 10.5 pg/mL | 2.04-4.4 pg/mL | |||||
| T3: 251 ng/dL | 64-181 ng/dL | |||||
| FT4: 3.57 ng/d | 0.93-1.71 ng/dL | |||||
| Case 2 | TSH: <0.001 μgUi/mL | 0.27-4.4 μgUi/mL | •TRAb: 5.85 IU/ml •TSI:NA •Anti TPO: 833 IU/ml†† •Anti Tg: 33 IU/ml§ |
NA | NA | |
| FT3: 9.2 pg/mL | 2.04-4.4 pg/mL | |||||
| T3: 216 ng/dL | 64-181 ng/dL | |||||
| FT4: 1.84 ng/d | 0.93-1.71 ng/dL | |||||
| Weintraub, 2021, (24) USA |
Case 1 | TSH: <0.008 | 0.45-4.5 μIU/ml | •TRAb: 32 IU/L •TSI: >40 •Anti TPO: 1730 IU/ml† •Anti Tg: NA |
Heterogeneous, hypervascular, enlarged gland | NA |
| FT3: NA | NA | |||||
| T3: 10.3 nmol/L | 0.9-2.8 nmol/L | |||||
| FT4: 108 pmol/L | 10.6-22.8 pmol/L | |||||
| Case 2 | TSH: 0.011 μIU/ml | 0.45-4.5 μIU/ml | TRAb: 22 IU/L •TSI: NA •Anti TPO: 1149 IU/ml† •Anti Tg: NA |
Heterogeneous, hypervascular gland | Diffuse increased activity | |
| FT3: NA | NA | |||||
| T3: 4.6 nmol/L | 0.9-2.8 nmol/L | |||||
| FT4: 30.9 pmol/L | 10.6-22.8 pmol/L | |||||
| Case 3 | TSH: 0.005 μIU/ml | 0.45-4.5 μIU/ml | •TRAb: NA •TSI: NA •Anti TPO: 15 IU/ml† •Anti Tg: NA |
NA | NA | |
| FT3: NA | NA | |||||
| T3: 2.5 nmol/L | 0.9-2.8 nmol/L | |||||
| FT4: 22.9 | 10.6-22.8 pmol/L | |||||
| Yamamoto, 2021, (28) Japan |
Case 1 | TSH: <0.008 mIU/mL | NA | •TRAb: 33.8 IU/L •TSI: NA •Anti TPO: NA •Anti Tg: NA |
Goitre lesions | NA |
| FT3: 23.2 ng/dL | NA | |||||
| T3: NA | NA | |||||
| FT4: 3.3 ng/dL | NA | |||||
| Zettinig, 2021, (33) Austria |
Case 1 | TSH: NA | NA | •TRAb: 4.2 •TSI: NA •Anti TPO: NA •Anti Tg: NA |
NA | NA |
| FT3: 11.10 pg/mL | 2.15–4.12 pg/mL | |||||
| T3: NA | NA | |||||
| FT4: 3.56 ng/dL | 0.70–1.70 ng/dL | |||||
| Case 2 | TSH: NA | NA | •TRAb: 2.9 •TSI: NA •Anti TPO: NA •Anti Tg: NA |
NA | NA | |
| FT3: 5.18 pg/mL | 2.15–4.12 pg/mL | |||||
| T3: NA | NA | |||||
| FT4: 1.63 ng/dL | 0.70–1.70 ng/dL |
Ab, Antibodies; Anti Tg, Antithyroglobulin; RAIU, radioactive iodine uptake test; TRAb, thyroid receptor antibody; TSI, thyroid stimulating immunoglobulin; TSH, thyroid stimulating hormone; TPO, Thyroid peroxidase; NA, not available.
Normal range: TRAb <1.5 IU/L, *<1 IU/L, ** <1.75 IU/L, ***<2.9IU/L, ****<0.55 IU/L, *****<10%.
Anti TPO: 0–34 IU/ml, † <9 IU/ml, †† 0-5.6 IU/ml.
Anti-TG: 0–115 IU/ml, § <40 IU/mL, §§ <4 IU/mL, §§§ 0-30 IU/ml, § § § § <14.4 IU/ml.
TSI<140%, ‡<125%, ‡‡<0.7 IU/ml, ‡‡‡ <0.55 IU/ml.
Quality of the studies
The mean quality score indicated that the studies reported on average 10 of the recommended 12 elements, defined by the guidelines. Only 3 studies had a perfect score of 12 while the second most common score was 11. The most frequently missing information was the following: adverse events after vaccine administration (76%, 16/21) ( Table 3 ).
Table 3.
Quality assessment of the included studies.
| Author, year | Q1 | Q2 | Q3 | Q4 | Q5 | Q6 | Q7 | Q8 | Q9 | Q10 | Q11 | Q12 | Overall |
| Bostan, 2022 (38) | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ○ | ● | 11 |
| Chee, 2022 (39) | ● | ● | ● | ● | ● | ○ | ● | ● | ● | ● | ○ | ● | 10 |
| Chua, 2022 (37) | ● | ● | ● | ● | ● | ○ | ● | ● | ● | ● | ● | ● | 11 |
| Di Fillipo, 2021 (35) | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | 12 |
| Goblirsch, 2021 (23) | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ○ | ● | 11 |
| Hamouche, 2021 (25) | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | 12 |
| Lee, 2021 (41) | ● | ● | ● | ○ | ● | ○ | ● | ● | ● | ● | ○ | ● | 9 |
| Lui, 2021 (20) | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | 12 |
| Oguz, 2022 (36) | ● | ● | ● | ● | ● | ○ | ● | ● | ● | ● | ○ | ● | 10 |
| Patrizio, 2021 (30) | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ○ | ● | 11 |
| Pierman, 2021 (29) | ● | ● | ● | ● | ● | ○ | ● | ● | ● | ● | ○ | ● | 10 |
| Pla Pleris, 2022 (22) | ● | ● | ● | ○ | ● | ○ | ● | ○ | ● | ● | ○ | ● | 8 |
| Pujol, 2021 (27) | ● | ● | ● | ● | ● | ○ | ● | ● | ● | ● | ○ | ● | 10 |
| Raven, 2021(40) | ● | ● | ● | ● | ● | ○ | ● | ● | ● | ● | ○ | ● | 10 |
| Shih, 2022 (42) | ● | ● | ● | ○ | ● | ○ | ● | ○ | ● | ○ | ○ | ● | 7 |
| Sriphrapradang, 2021 (31 (I) | ● | ● | ● | ○ | ● | ● | ● | ● | ● | ● | ○ | ● | 10 |
| Sriphrapradang, 2021 (32 (II) | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ○ | ● | 11 |
| Vera- Lastra, 2021(34) | ● | ● | ● | ● | ● | ○ | ● | ○ | ● | ● | ○ | ● | 9 |
| Weintraub, 2021(24) | ● | ● | ● | ○ | ● | ● | ● | ● | ● | ● | ○ | ● | 10 |
| Yamamoto, 2021(28) | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | 12 |
| Zettining, 2021(33) | ● | ● | ● | ● | ● | ○ | ● | ● | ● | ○ | ○ | ● | 9 |
Q1 ,Appropriate title; Q2, Patient demographics; Q3, Current health status; Q4, Medical History; Q5, Physical examination; Q6, Patient disposition; Q7, Drug Identification; Q8, Dosage; Q9, Administration; Q10, Drug-reaction interface; Q11, Adverse events; Q12, Discussion ● = 1; ○ = No.
Discussion
COVID-19 vaccine administration has not been considered a triggering factor for thyroid autoimmune disorders. However, emerging evidence, mainly from case reports and case series, suggests a potential association between COVID-19 vaccination and the development or recurrence of thyroid dysfunction including Graves’ disease. In our systematic review, we comprehensively examined the currently available literature to provide an overview of the reported cases of Graves’ disease following vaccination against SARS-CoV-2. Our study included 21 reports, which comprised 57 patients, in which Graves’ disease was reported after the administration of different COVID-19 vaccines. The onset of the symptoms started after administration of the first dose in most cases and clinical improvement was reported for the majority of patients.
Results in the context of the literature
Graves’ disease is an autoimmune disorder most commonly presenting with hyperthyroidism and seropositivity for autoantibodies against the thyrotropin receptor (43–45). TRAb production is secondary to a Th1 immune response in which T cells react with peptides derived from thyroid autoantigens leading to increased secretion of autoantibodies from B cells. TRAb stimulates thyroid hormone synthesis, which leads to thyroid growth and diffuse goiter. Multiple precipitating factors have been proposed including female gender, genetic predisposition, stress, smoking, medication, iodine, pregnancy and infection. Several cases of Graves’ disease have been reported following COVID-19 infection with the T cell sensitization to the TSH receptor antigen being proposed as the driving mechanism in people with genetic predisposition (45). Specifically, in a systematic review, Tutal et al. reported 14 cases of Graves’ disease post COVID-19 infection (45).
Apart from COVID-19 infection, our study showed that COVID-19 vaccination may potentially be associated with Graves’ disease although evidence is still inconclusive. Following the sex distribution reported in the literature (46), Graves’ disease post vaccination presented most commonly in females (75%) with palpitations and weight loss. Overall, 19 people had a pre-existing thyroid disorder such as multinodular goiter, Graves’ disease, autoimmune thyroiditis or subclinical hypothyroidism. Interestingly, most patients with background thyroid dysfunction had received an mRNA vaccine. Regrettably, the impact of previous COVID-19 infection could not be assessed considering the lack of data in the majority of cases but remains a possibility. Based on the short interval between vaccination and initiation of symptoms, Graves’ disease might have preceded vaccination on certain occasions. As expected, most cases were treated with thionamides and beta blockers. Steroids were used only in three cases for the amelioration of symptoms by reducing the conversion of T4 to T3. Although steroids consist one of the main therapeutic approaches in people with subacute thyroiditis, more concrete instructions on their use in Graves’ disease are needed considering their potential impact on the immune response triggered by vaccination.
Two reviews have attempted to present the evidence on thyroid dysfunction and COVID-19 vaccination so far. Caironi et al. and Jafarzadeh et al. included 29 and 21 number of patients with Graves’ disease respectively (47, 48). Our study focused solely on Graves’ disease including 57 patients. Overall our findings were in agreement regarding presenting symptoms, onset of symptoms post-vaccination and management. Distribution on different vaccine types was also similar.
Although the exact mechanism behind the potential association between COVID-19 vaccination and Graves’ disease remains to be elucidated, several theories have been suggested. Autoimmune/inflammatory syndrome induced by adjuvants (ASIA) is the most frequently cited theory (49). Adjuvants are used to increase immune response to the active substance and although essential for adequate immune system stimulation, they have been considered the etiological factor of ASIA following Hepatitis B and HPV immunization in the past most likely due to an intense immune response or genetic predisposition (50). This results from the formation of autoantibodies or systemic/localised inflammation, it rarely involves autoimmune thyroid disease and it’s most commonly reported within the first 3 weeks post vaccination (51). Although, mRNA vaccines do not use of adjuvants, they contain lipid nanoparticles which facilitate mRNA transport into cells and could potentially induce immune response in predisposed people (52). Additionally, the presence of the ACE-2 receptor in the thyroid gland could offer another explanation for the endocrine effects reported in individuals following the SARS-CoV-2 infection or vaccination since it constitutes the entry point of the virus into host cells (53). Cellular entry could lead to a direct inflammatory or immune mediated injury on thyroid cells with subsequent clinical manifestations (54). It is worth noting that the mRNA of ACE-2 receptor is also expressed in thyroid cells as confirmed by studies in thyroid tissue specimens and cultures, making them a potential target for viral entry (55, 56).
Another theory includes the possible effect of molecular mimicry in the development of autoimmune thyroid disorders (29). Thyroid peroxidase peptide sequences in thyroid tissue share similarities with the SARS-CoV-2 proteins, such as the spike protein that comprise a major target of the mRNA vaccines (57). It has been speculated that this could lead to cross-recognition between the modified SARS-CoV-2 spike protein encoded in the mRNA vaccine and the thyroid target proteins resulting in autoimmunity and it has been demonstrated that spike protein, nucleoprotein and membrane protein all cross-react with thyroid peroxidase (57). Additionally, cytokines such as Interferon gamma have been identified in both Graves’ disease and the SARS-CoV-2 infection (58). Results from a phase I/II vaccine candidate mRNA BNT162b1 suggest a Th1 type immune response involving interferon gamma, which could imply a modification of the cytokine environment that could favor the Th1 population and subsequently the production of autoantibodies (59).
Strengths and limitations
Our study is the first to systematically review the association between COVID-19 vaccination and onset or exacerbation of Graves’ disease. Our findings present a comprehensive review of the currently available literature and highlight published data with rigorous quality assessment of included studies.
However, some limitations still persist. A broader drawback underlies the low-quality nature of case reports and case series included in our review, which affects the validity and scope of conclusions that can be reached. Specifically, the potential risk of bias of these studies is inevitable, as these are exposed to the risk of overinterpretation and selection bias. In this way, their reported data although interesting may be far from the truth without reflecting a valid description. Thus, causality cannot be inferred and requires insight from mechanistic studies.
Conclusion
Although the currently available COVID-19 vaccines have established a safe profile and the benefits of vaccination outweigh the possible adverse events, patients can potentially experience mild to moderate side effects including thyroid related complications. Graves’ disease is possibly a condition physicians and other healthcare professionals may expect to see in patients receiving COVID-19 vaccines. While the above adverse event is rare, considering the scarcity of available data in scientific literature, and causality is not yet confirmed, the increased awareness of clinicians and the early recognition of the disorder is important for the optimal management of these patients.
Data availability statement
The original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding author.
Author contributions
Conceptualization, KKT, KSK; Methodology, KKT, KSK; Validation, KKT, DS, KSK; Investigation, KKT, KSK; Resources, KKT, DS, KSK; Writing—Original Draft Preparation, KKT, PG, DS, KSK; Writing—Review & Editing, KKT, DS, KSK; Visualization, KKT, DS, KSK; Supervision, DS, KSK; Project Administration, PG, DS, KSK. All authors have read and agreed to the published version of the manuscript.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
- 1. Lu H, Stratton CW, Tang YW. Outbreak of pneumonia of unknown etiology in wuhan, China: The mystery and the miracle. J Med Virol (2020) 92(4):401. doi: 10.1002/jmv.25678 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2. Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in wuhan, China: A single-centered, retrospective, observational study. Lancet Respir Med (2020) 8(5):475–81. doi: 10.1016/S2213-2600(20)30079-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3. Kechagias K, Giannos P, Katsikas Triantafyllidis K, Falagas ME. Spotlight on early COVID-19 research productivity: A 1-year bibliometric analysis. Front Public Health (2022) 10:811885. doi: 10.3389/fpubh.2022.811885 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4. Patel N, Nicolae R, Geropoulos G, Mandal P, Christou C, Gavala M, et al. Pneumomediastinum in the COVID-19 era: To drain or not to drain? Monaldi Arch Chest Dis (2022). doi: 10.4081/monaldi.2022.2338 [DOI] [PubMed] [Google Scholar]
- 5. Loubet P, Wittkop L, Tartour E, Parfait B, Barrou B, Blay J, et al. A French cohort for assessing COVID-19 vaccine responses in specific populations. Nat Med (2021) p:1–3. doi: 10.1038/s41591-021-01435-1 [DOI] [PubMed] [Google Scholar]
- 6. Tanriover MD, Doganay HL, Akova M, Guner HR, Azap A, Akhan S, et al. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. Lancet (2021) 398(10296):213–22. doi: 10.1016/S0140-6736(21)01429-X [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7. Mathieu E, Ritchie H, Ortiz-Ospina E, Roser M, Hasell J, Appel C, et al. A global database of COVID-19 vaccinations. Nat Hum Behav (2021) 5(7):947–53. doi: 10.1038/s41562-021-01122-8 [DOI] [PubMed] [Google Scholar]
- 8. Livingston EH, Malani PN, Creech CB. The Johnson & Johnson vaccine for COVID-19. Jama (2021) 325(15):1575–5. doi: 10.1001/jama.2021.2927 [DOI] [PubMed] [Google Scholar]
- 9. Mulligan MJ, Lyke KE, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults. Nature (2020) 586(7830):589–93. doi: 10.1038/s41586-020-2639-4 [DOI] [PubMed] [Google Scholar]
- 10. Barrett JR, Belij-Rammerstorfer S, Dold C, Ewer KJ, Folegatti PM, Gilbride C, et al. Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses. Nat Med (2021) 27(2):279–88. doi: 10.1038/s41591-020-01179-4 [DOI] [PubMed] [Google Scholar]
- 11. Anderson EJ, Rouphael NG, Widge AT, Jackson LA, Roberts PC, Makhene M, et al. Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults. New Engl J Med (2020) 383(25):2427–38. doi: 10.1056/NEJMoa2028436 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12. Katsikas Triantafyllidis K, Giannos P, Mian IT, Kyrtsonis G, Kechagias KS. Varicella zoster virus reactivation following COVID-19 vaccination: A systematic review of case reports. Vaccines (2021) 9(9):1013. doi: 10.3390/vaccines9091013 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13. Giannos P, Katsikas Triantafyllidis K, Geropoulos G, Kechagias KS. Persistent hiccups as an atypical presentation of SARS-CoV-2 infection: A systematic review of case reports. Front Neurol (2022) 13. doi: 10.3389/fneur.2022.819624 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14. Giannos P, Prokopidis K. Gut dysbiosis and long COVID-19: Feeling gutted. J Med Virol (2022) 94(7):2917–8. doi: 10.1002/jmv.27684 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15. Dias L, Soares-Dos-Reis R, Meira J, Ferrao D, Soares PR, Pastor A, et al. Cerebral venous thrombosis after BNT162b2 mRNA SARS-CoV-2 vaccine. J Stroke Cerebrovascular Dis (2021) 30(8):105906. doi: 10.1016/j.jstrokecerebrovasdis.2021.105906 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16. Bril F, Diffalha SA, Dean M, Fettig DM. Autoimmune hepatitis developing after coronavirus disease 2019 (COVID-19) vaccine: Causality or casualty? J Hepatol (2021) 75(1):222–4. doi: 10.1016/j.jhep.2021.04.003 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17. Vuille-Lessard É́, Montani M, Bosch J, Semmo N. Autoimmune hepatitis triggered by SARS-CoV-2 vaccination. J Autoimmun (2021) 123:102710. doi: 10.1016/j.jaut.2021.102710 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18. Scappaticcio L, Pitoia F, Esposito K, Piccardo A, Trimboli P. Impact of COVID-19 on the thyroid gland: an update. Rev endocrine Metab Disord (2021) 22(4):803–15. doi: 10.1007/s11154-020-09615-z [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19. Mateu-Salat M, Urgell E, Chico A. SARS-COV-2 as a trigger for autoimmune disease: report of two cases of graves’ disease after COVID-19. J endocrinological Invest (2020) 43(10):1527–8. doi: 10.1007/s40618-020-01366-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20. Lui DTW, Lee CH, Chow WS, Lee ACH, Tam AR, Fong CHY, et al. Thyroid dysfunction in relation to immune profile, disease status, and outcome in 191 patients with COVID-19. J Clin Endocrinol Metab (2021) 106(2):e926–35. doi: 10.1210/clinem/dgaa813 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21. Kelly WN, Arellano FM, Barnes J, Bergman U, Edwards RI, Fernandez AM, et al. Guidelines for submitting adverse event reports for publication. Pharmacoepidemiology Drug Saf (2007) 16(5):581–7. doi: 10.1002/pds.1399 [DOI] [PubMed] [Google Scholar]
- 22. Pla Peris B, Alfaro AAM, Royo FJM, Galiana PA, Naranjo SP, Boillos MG, et al. Thyrotoxicosis following SARS-COV-2 vaccination: A case series and discussion. J Endocrinological Invest (2022) 45(5):1071–7. doi: 10.1007/s40618-022-01739-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23. Goblirsch TJ, Paulson AE, Tashko G, Mekonned AJ. Graves’ disease following administration of second dose of SARS-CoV-2 vaccine. BMJ Case Rep CP (2021) 14(12):e246432. doi: 10.1136/bcr-2021-246432 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24. Weintraub MA, Ameer B, Sinha Gregory N. Graves disease following the SARS-CoV-2 vaccine: Case series. J Invest Med High Impact Case Rep (2021) 9:23247096211063356. doi: 10.1177/23247096211063356 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25. Hamouche W, El Soufi Y, Okafor BV, Zhang F, Paras C. A case report of new onset graves’ disease induced by SARS-CoV-2 infection or vaccine? J Clin Trans Endocrinology: Case Rep (2022) 23:100104. doi: 10.1016/j.jecr.2021.100104 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26. Lui DTW, Lee KK, Lee CH, Lee ACH, Hung IFN, Tan KCB. Development of graves' disease after SARS-CoV-2 mRNA vaccination: A case report and literature review. Front Public Health (2021) 9. doi: 10.3389/fpubh.2021.778964 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27. Pujol A, Gomez LA, Gallegos C, Nicolau J, Sanchis P, Gonzalez-Freire M, et al. Thyroid as a target of adjuvant autoimmunity/inflammatory syndrome due to mRNA-based SARS-CoV2 vaccination: From graves’ disease to silent thyroiditis. J Endocrinological Invest (2022) 45(4):875–82. doi: 10.1007/s40618-021-01707-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28. Yamamoto K, Mashiba T, Takano K, Suzuki T, Kami M, Takita M, et al. A case of exacerbation of subclinical hyperthyroidism after first administration of BNT162b2 mRNA COVID-19 vaccine. Vaccines (2021) 9(10):1108. doi: 10.3390/vaccines9101108 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29. Pierman G, Delgrange E, Jonas C. Recurrence of graves’ disease (a Th1-type cytokine disease) following SARS-CoV-2 mRNA vaccine administration: A simple coincidence? Eur J Case Rep Internal Med (2021) 8(9):2807. doi: 10.12890/2021_002807 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30. Patrizio A, Ferrari SM, Antonelli A, Fallahi P. A case of graves' disease and type 1 diabetes mellitus following SARS-CoV-2 vaccination. J Autoimmun (2021) 125:102738. doi: 10.1016/j.jaut.2021.102738 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31. Sriphrapradang C, Shantavasinkul PC. Graves’ disease following SARS-CoV-2 vaccination. Endocrine (2021) 74(3):473–4. doi: 10.1007/s12020-021-02902-y [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32. Sriphrapradang C. Aggravation of hyperthyroidism after heterologous prime-boost immunization with inactivated and adenovirus-vectored SARS-CoV-2 vaccine in a patient with graves’ disease. Endocrine (2021) 74(2):226–7. doi: 10.1007/s12020-021-02879-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33. Zettinig G, Krebs M. Two further cases of graves’ disease following SARS-Cov-2 vaccination. J Endocrinological Invest (2022) 45(1):227–8. doi: 10.1007/s40618-021-01650-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34. Vera-Lastra O, Navarro AO, Domiguez MPC, Medina G, Valadez TIS, Jara LJ. Two cases of graves' disease following SARS-CoV-2 vaccination: An autoimmune/inflammatory syndrome induced by adjuvants. Thyroid (2021) 31(9):1436–9. doi: 10.1089/thy.2021.0142 [DOI] [PubMed] [Google Scholar]
- 35. di Filippo L, Castellino L, Giustina A. Occurrence and response to treatment of graves’ disease after COVID vaccination in two male patients. Endocrine (2022) 75(1):19–21. doi: 10.1007/s12020-021-02919-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36. Oğuz SH, Sendur SN, Iremli BG, Gurlek A, Erbas T, Unluturk U. SARS-CoV-2 vaccine–induced thyroiditis: Safety of revaccinations and clinical follow-up. J Clin Endocrinol Metab (2022) 107(5):e1823–34. doi: 10.1210/clinem/dgac049 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37. Chua MWJ. Graves' disease after COVID-19 vaccination. Ann Acad Medicine Singapore (2022) 51(2):127–8. doi: 10.47102/annals-acadmedsg.2021398 [DOI] [PubMed] [Google Scholar]
- 38. Bostan H, Ucan B, Kizilgul M, Calapkulu M, Hepsen S, Gul U, et al. Relapsed and newly diagnosed graves’ disease due to immunization against COVID-19: A case series and review of the literature. J Autoimmun (2022) 128:102809. doi: 10.1016/j.jaut.2022.102809 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39. Chee YJ, Liew H, Hoi WH, Lee Y, Lim B, Chin HX, et al. SARS-CoV-2 mRNA vaccination and graves’ disease: A report of 12 cases and review of the literature. J Clin Endocrinol Metab (2022) 107(6):e2324–30. doi: 10.1210/clinem/dgac119 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40. Raven LM, McCormack AI, Greenfield JR. Letter to the Editor from raven et al:”Three cases of subacute thyroiditis following SARS-CoV-2 vaccine”. J Clin Endocrinol Metab (2022) 107(4):e1767–8. doi: 10.1210/clinem/dgab822 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41. Lee K, Kim YJ, Jin HY. Thyrotoxicosis after COVID-19 vaccination: seven case reports and a literature review. Endocrine (2021) 74(3):470–2. doi: 10.1007/s12020-021-02898-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42. Shih S-R, Wang C-Y. SARS-CoV-2 vaccination related hyperthyroidism of graves’ disease. J Formosan Med Assoc (2022) doi: 10.1016/j.jfma.2022.02.010. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43. Mills KH. Regulatory T cells: friend or foe in immunity to infection? Nat Rev Immunol (2004) 4(11):841–55. doi: 10.1038/nri1485 [DOI] [PubMed] [Google Scholar]
- 44. Benvenga S, Guarneri F. Molecular mimicry and autoimmune thyroid disease. Rev Endocrine Metab Disord (2016) 17(4):485–98. doi: 10.1007/s11154-016-9363-2 [DOI] [PubMed] [Google Scholar]
- 45. Tutal E, Ozaras R, Leblebicioglu H. Systematic review of COVID-19 and autoimmune thyroiditis. Travel Med Infect Dis (2022) p:102314. doi: 10.1016/j.tmaid.2022.102314 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 46. Manji N, Carr-Smith JD, Boelaert K, Allahabadia A, Armitage M, Chatterjee VK, et al. Influences of age, gender, smoking, and family history on autoimmune thyroid disease phenotype. J Clin Endocrinol Metab (2006) 91(12):4873–80. doi: 10.1210/jc.2006-1402 [DOI] [PubMed] [Google Scholar]
- 47. Caironi V, Pitoia F, Trimboli P. Thyroid inconveniences with vaccination against SARS-CoV-2: The size of the matter. a systematic review. Front Endocrinol (Lausanne) (2022) 13:900964. doi: 10.3389/fendo.2022.900964 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 48. Jafarzadeh A, Nemati M, Jafarzadeh S, Nozari P, Mortazavi SMJ. Thyroid dysfunction following vaccination with COVID-19 vaccines: A basic review of the preliminary evidence. J Endocrinol Invest (2022) p:1–29. doi: 10.1007/s40618-022-01786-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 49. Shi S, Zhu H, Xia X, Liang Z, Ma X, Sun B. Vaccine adjuvants: Understanding the structure and mechanism of adjuvanticity. Vaccine (2019) 37(24):3167–78. doi: 10.1016/j.vaccine.2019.04.055 [DOI] [PubMed] [Google Scholar]
- 50. Bragazzi NL, Hejly A, Watad A, Adawi M, Amital H, Shoenfeld Y. ASIA syndrome and endocrine autoimmune disorders. Best Pract Res Clin Endocrinol Metab (2020) 34(1):101412. doi: 10.1016/j.beem.2020.101412 [DOI] [PubMed] [Google Scholar]
- 51. Das L, Bhadada SK, Sood A. Post-COVID-vaccine autoimmune/inflammatory syndrome in response to adjuvants (ASIA syndrome) manifesting as subacute thyroiditis. J Endocrinol Invest (2022) 45(2):465–7. doi: 10.1007/s40618-021-01681-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 52. Chen BM, Cheng TL, Roffler SR. Polyethylene glycol immunogenicity: Theoretical, clinical, and practical aspects of anti-polyethylene glycol antibodies. ACS Nano (2021) 15(9):14022–48. doi: 10.1021/acsnano.1c05922 [DOI] [PubMed] [Google Scholar]
- 53. Lazartigues E, Qadir MMF, Mauvais-Jarvis F. Endocrine significance of SARS-CoV-2's reliance on ACE2. Endocrinology (2020) 161(9):108. doi: 10.1210/endocr/bqaa108 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 54. Soldevila B, Puig-Domingo M, Marazuela M. Basic mechanisms of SARS-CoV-2 infection. What endocrine systems could be implicated? Rev Endocr Metab Disord (2022) 23(2):137–50. doi: 10.1007/s11154-021-09678-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 55. Rotondi M, Coperchini F, Ricci G, Denegri M, Groce L, Ngnitejeu ST, et al. Detection of SARS-COV-2 receptor ACE-2 mRNA in thyroid cells: A clue for COVID-19-related subacute thyroiditis. J Endocrinol Invest (2021) 44(5):1085–90. doi: 10.1007/s40618-020-01436-w [DOI] [PMC free article] [PubMed] [Google Scholar]
- 56. İremli BG, Şendur SN, Ünlütürk U. Three cases of subacute thyroiditis following SARS-CoV-2 vaccine: Postvaccination ASIA syndrome. J Clin Endocrinol Metab (2021) 106(9):2600–5. doi: 10.1210/clinem/dgab373 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 57. Vojdani A, Vojdani E, Kharrazian D. Reaction of human monoclonal antibodies to SARS-CoV-2 proteins with tissue antigens: Implications for autoimmune diseases. Front Immunol (2020) 11:617089. doi: 10.3389/fimmu.2020.617089 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 58. Croce L, Gangemi D, Ancona G, Liboa F, Bendotti G, Minelli L, et al. The cytokine storm and thyroid hormone changes in COVID-19. J Endocrinol Invest (2021) 44(5):891–904. doi: 10.1007/s40618-021-01506-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 59. Sahin U, Muik A, Derhovanessian E, Vogler I, Kranz LM, Vormehr M, et al. COVID-19 vaccine BNT162b1 elicits human antibody and T(H)1 T cell responses. Nature (2020) 586(7830):594–9. doi: 10.1038/s41586-020-2814-7 [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Data Availability Statement
The original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding author.